NICE recommends weight loss drug semaglutide for obese adults
Source : https://www.bmj.com/content/376/bmj.o340
Adults who have weight related comorbidity and a BMI of at least 35 (or lower under certain circumstances) should be offered the weight loss drug semaglutide alongside a diet and...
Conclusion: "Adults who have weight related comorbidity and a BMI of at least 35 (or lower under certain circumstances) should be offered the weight loss drug semaglutide alongside a diet and exercise plan, NICE has said."
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35064550/
doi: 10.1007/s41669-021-00317-z. Online ahead of print. 1 Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital, 41345, Gothenburg, Sweden. [email protected]. 2 Novo Nordisk Scandinavia...
Conclusions: In a Swedish setting, oral semaglutide was cost effective compared with empagliflozin and sitagliptin for patients with T2D inadequately controlled on oral glucose-lowering drugs.
Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
Obesity is a global public-health problem. As of 2015, ~2.2 billion are overweight or obese worldwide. Obesity is accompanied by multiple problems, such as reduced exercise capacity, worse quality of...
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-022-00982-3
Purpose of Review To review the currently available data on the effect of Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on postprandial lipaemia. Recent Findings Out of the available studies...
Conclusion/Relevance: GLP-1 RAs have consistent beneficial effects on postprandial lipaemia with most of the data coming from studies with exenatide and liraglutide. Reduction of postprandial lipaemia might be one of the mechanisms behind the pleiotropic effects of GLP-1 RAs.
Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35098383/
The kidney has a prominent role in maintaining glucose homeostasis by using glucose as a metabolic substrate. This occurs by generating glucose through gluconeogenesis, and by reuptaking filtered glucose through...
Conclusion/Relevance: In current review, we examine the role of SGLT2 and SGLT1 in the regulation of renal glucose reabsorption in health and disease and the effect of SGLT2 inhibition on clinical outcomes of populations with different cardiovascular conditions investigated with large-scale outcome trials.